COMP <GO>
JNJ vs UNH // REVENUE GROWTH (YOY)
Johnson & Johnson (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: JNJ 8
— UNH 7
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JNJ VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JNJ | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.90% | 88.57% | -20.67 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.50% | 11.47% | +14.03 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.5x | 16.4x | +2.05 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.97% | 6.48% | -3.51 | UNH | /fcf-yield <GO> |
| Operating Margin | 34.70% | 4.82% | +29.88 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 28.50% | 3.14% | +25.36 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 6.00% | 6.46% | -0.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.59 | 3.12 | +2.47 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 56.0 | +4.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.33 | +0.75 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 17.1x | +5.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $662.49B | $364.66B | $297.83B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JNJ REV | UNH REV | JNJ GROSS % | UNH GROSS % | JNJ FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $94.19B | $447.57B | 67.9% | 88.7% | $19.70B | $16.07B |
| FY 2024 | $88.82B | $400.28B | 69.1% | 88.3% | $19.84B | $20.70B |
| FY 2023 | $85.16B | $371.62B | 44.0% | 89.6% | $18.96B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JNJ // BETA 1.08
UNH // BETA 0.33